Pricing Log in Create free account

Phathom Pharmaceuticals, Inc. (PHAT) vs Sagimet Biosciences Inc. (SGMT)

Phathom Pharmaceuticals, Inc. and Sagimet Biosciences Inc. are both Biotechnology companies. Phathom Pharmaceuticals, Inc. and Sagimet Biosciences Inc. are of similar size ($606.8M and $574.7M). Sagimet Biosciences Inc. has the higher net margin (0.00% vs −41.3%) and the lower return on invested capital (−205.2% vs 0.00%). Across the 13 metrics below, Phathom Pharmaceuticals, Inc. leads on 7 and Sagimet Biosciences Inc. on 6.

Valuation

Metric PHAT SGMT Biotechnology median
P/E n/m n/m 8.50
P/S 2.42 n/m 9.71
P/B n/m 1.66 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 2.39 n/m 9.21
Earnings yield (18.50%) (15.96%) (33.15%)
Free cash flow yield (6.37%) (9.79%) (25.50%)

Profitability

Metric PHAT SGMT Biotechnology median
Gross margin 82.92% 0.00% 65.16%
Operating margin (16.96%) 0.00% 0.00%
Net margin (41.34%) 0.00% 0.00%
Free cash flow margin (15.40%) 0.00% 0.00%
Return on equity 26.42% (24.37%) (56.36%)
Return on assets (34.32%) (23.49%) (48.04%)
Return on invested capital 0.00% (205.24%) 0.00%

Growth

Metric PHAT SGMT Biotechnology median
Revenue growth (TTM) 110.16% — 6.02%
EPS growth (last fiscal year) 42.72% (8.97%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PHAT SGMT Biotechnology median
Debt to equity (0.48) 0.00 0.00
Current ratio 1.92 45.02 4.72
Net debt to EBITDA (0.51) 1.98 0.96

Dividend

Metric PHAT SGMT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric PHAT SGMT Biotechnology median
Market cap 606.76m 574.68m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack